JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus
Eli Lilly highlighted elevated Lp(a) as a major unmet need within a broader cardiometabolic strategy.
16 January 2026
16 January 2026
Eli Lilly highlighted elevated Lp(a) as a major unmet need within a broader cardiometabolic strategy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.